Portal do Butantan

Five studies to understand why CoronaVac is the best vaccine for those with comorbidity

Publicado em: 01/01/1970

Those who contract Covid-19 and already have some kind of comorbidity, have a bigger chance to evolve to a serious case than someone healthy. According to the National Operalization of Vaccine against Covid-19 Plan, from the Healthy Ministry, patients with mellitus diabetics have an over risk increased in 4,2 times in front of SARS-Cov-2; Those who have chronic kidney disease have an over risk of 3,2; and people with lung disease, an over risk of 2,2. That’s the reason, the 22 million Brazilians with comorbidity between 18 and 59 years-old were the 14º group to be vaccinated in Brazil, after the eldery.

Besides having a greater risk of developing a serious case of Covid-19, people with comorbidity also must be more cautious to any kind of medicine, since they can suffer from adverse effects that were not predicted. And that’s the reason why the CoronaVac, Butantan and biopharmaceutical Sinovac’s vaccine, it’s the most recommended to people with comorbidity. Besides having the higher profile of safety among the available immunizing in Brazil against the Covid-19, several researches proved its efficiency in this group.


The Butantan Team compiled the five mais scientific researches that shows the effectiveness of CoronaVac to groups of risk, patients with comorbidity and immunosuppressed.

The impact of CoronaVac in people with comorbidity and immunosuppressed are one of the topics discussed in CoronaVac Symposium, an international symposium organized by Butantan with the support of Sinovac to discuss the most recent data about the vaccine against Covid-19.The event will be online and happen on the days 7,8 and 9/12. Know more and sign up on the website coronavacsymposium.butantan.gov.br.


CoronaVac generates high protection against Covid-19 in patients that live with B Hepatitis

The conclusion is part of a study published by Chinese researchers in an article in the Cellular & Molecular Immunology magazine, from the group Nature, in 15/11. According to the research, after receiving the second dose of the immunizing, the patients presented a seroconversion tax o f87,25% to LgG antibodies and of 74,5% to neutralize antibodies. The work was realized by researchers of the Medicine College of the Science and Technology University of Huazhong, from Wuhan, in China, where the pandemics of Covid-19 ecloded. 284 patients with chronic infection of B hepatitis took participation on the study, and 81 of them were not vaccinated, 54 had only the first dose of the vaccine, and 149 did complete the vaccine scheme of two doses.


CoronaVac brings high levels of protection to people with HIV

Two scientific studies published by researchers from Brazil and from China evidenced that the CoronaVac is safe and capable of generating high levels of protection against the SARS-CoV-2 on people infected by the HIV virus, the cause of AIDS. The work “Safety and Immunogenicity of CoronaVac in People living with HIV”, realized by researchers of the Clinical Hospital from the Medicine College of the University of São Paulo and published in september on the preprints platform SSRN, evaluated the safety and immunogenicity of the CoronaVac on 215 people that live with HIV, in comparison with 296 people without immunosuppression known. All the participants received two doses of CoronaVac with a break of 28 days. Four weeks after the second dose of the vaccine, the percentage of participants with positive for SC and NAb neutralizer antibodies was high for the HIV group and the control group. No adverse reaction was related during the study among people with HIV nor the non immunosuppressed participants.

In october, another study realized by chinese and published on the SSRN platform brought evidences that CoronaVac is safe to people living with the HIV, and that the people from that group, when fully immunized on the scheme of two doses of the Butantan Vaccine’s, can reach high levels of protection against SARS-CoV-2, similar to the one observed on the HIV-negative individuals.


CoronaVac is efficient against COVID-19 in patients with cancer 

A study held by researchers working in seven hospitals and two universities in Ancara, Turkey, and published in the beginning of august in the magazine Future Oncology, showed that CoronaVac is efficient and generates protection in relation to Covid-19 in patients being treated against cancer. There was seroconversion (antibodies formation) in 63,8% of the people analized, two weeks after the administration of the second dose of the immunizing. The tax of immunogenicity reached 100% on patients who received only monoclonal antibody or immunotherapy as medicine. Besides, none of the patients presented infection by Covid-19 in a follow up about 85 days after completing the vaccine scheme. The break between the two applications of the CoronaVac doses was of 28 days.


CoronaVac increases in 70% antibodies against Covid-19 on immunosuppressed patients

Patients with autoimmune rheumatologic disease presented an increase of 70,4% on the level of antibodies against SARS-CoV-2 two weeks after receiving the second dose of CoronaVac. Besides increasing the seroconversion of the immunosuppressed patients, the CoronaVac also increased in 56,3% the amount of neutralizer antibodies. The conclusions are from a study realized by the Clinical Hospital of the Medicine College from the University of São Paulo (HCFMUSP) with 910 people and are described in an article released by the end of july on the Scientific Publication Nature Medicine. The results are extremely positive as it shows that CoronaVac is not just well accepted by the organism of immunosuppressed patients (those who have more difficult to produce antibodies), as it generates a high level of defensive antibodies and neutralizers. 


CoronaVac helps to improve immunity in transplanted patients

A study realized by researchers from Butantan Institute, from the Federal University of São Paulo (unifesp) and the Blood Center of Ribeirão Preto from the University of São Paulo (USP) showed that 43% of the kidney transplanted patients generated antibodies against Covid-19 15 days after receiving the second dose of CoronaVac (in other words, presented seroconversion). The work was developed at the Kidney Hospital and its preliminary results were disclosed in an article of the Transplantation magazine, the main mundial publication on the area of transplantation. The 910 immunosuppressed patients that participated in the research were vaccinated in two days. A little after the second dose, when the antibodies were still in reproduction, were 33 cases of Covid-19; 40 days after it, this number decreased to six cases.